Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives

Table 1

Principal clinical trials of chemotherapy plus Rituximab versus chemotherapy alone in NHL.

Lymphoma Subtype	Treatment	Patients (no.)	% Overall response rate (𝑃 value)*	Median Follow-up (mo.)	Reference
Follicular	CVP versus R-CVP	321	57 versus 81 (<.001)	53	Marcus et al. [28]
Follicular	CHOP versus R-CHOP	428	90 versus 96 (=.011)	18	Hiddemann et al. [29]
Follicular	CHOP versus R-CHOP	465	72.3 versus 85.1 (<.001)	39,4	van Oers et al. [30]
Follicular	FCM versus R-FCM	176	71 versus 95 (=.01)	26	Forstpointner et al. [31]
Follicular	MCP versus R-MCP	201	75 versus 92 (=.009)	47	Herold et al. [32]
relapsed/refractary low grade	R	37	46	13,4	Maloney et al. [33]
relapsed/refractary low grade	R	30	47	19	Feuring-Buske et al. [34]
relapsed/refractary low grade	R	166	48	19,5	McLaughlin et al. [35]
DLBCL	CHOP versus R-CHOP	399	63 versus 76 (=.005)*	24	Coiffier et al. [36]
DLBCL	CHOP versus R-CHOP	824	84 versus 93 (=.0001)**	34	Pfreundschuh et al. [37]
DLBCL	CHOP versus R-CHOP	632	57 versus 67 (=.05)**	42	Habermann et al. [38]
DLBCL	CHOP versus R-CHOP	122	75 versus 94 (=.0054)	18	Lenz et al. [39]
B-CLL	FC versus R-FC	552	58 versus 69.9 (=.0034)	25	Robak et al. [40]
B-CLL	FC versus R-FC	817	82.5 versus 87.2 (=.012)**	37,7	CLL8- German CLL Study Group*** [41]

*CR, CR-unconfirmed, partial response.
**CR rate.
***3-year OS.